Dr Maria Kinali MBBS, MD (UK), FRCPCH, FAAN Consultant Paediatric Neurologist, Honorary Senior Clinical Lecturer, Imperial College London, UK
CURRENT PROFESSIONAL and ACADEMIC EXPERIENCE
March 2019—Present: Lead Consultant Neurologist, The Portland Hospital, London, HCA Healthcare.
February 2012-Present: Consultant Paediatric Neurologist, The Portland Hospital, London, HCA Healthcare.
September 2009-Present: Consultant Paediatric Neurologist, Cromwell Hospital, London.
June 2009-Present: Honorary Senior Lecturer in Paediatric Neurology, Imperial College, London.
PAST PROFESSIONAL and ACADEMIC EXPERIENCE
June 2009-January 2018: Lead Consultant Paediatric Neurologist, Department of Paediatric Neurology, Chelsea and Westminster Foundation Trust (CWHFT), London.
January 2010-January 2018: Honorary Consultant Paediatric Neurologist, Royal Brompton Hospital, London.
April 2005-May 2009: Senior Clinical Research Fellow and Honorary Consultant in Neuromuscular Paediatrics, Hammersmith Hospital, Imperial College, transferred under TUPE to Institute of Child Health, University College London and Great Ormond Street Hospital, London.
April 2005-October 2008: Locum Consultant in Ambulatory Paediatrics, Hammersmith Hospital, Imperial College, London.
September 1997-December 2007: Resident in Paediatric Neurology, Clinical Fellow/Clinical Lecturer in Paediatric Neurology, UK.
May 1995-August 1997: Resident in Paediatrics, Greece.
QUALIFICATIONS
June 2008-Present: CCT in Paediatric Neurology, UK.
March 2001-Present: CCT in Paediatrics, UK.
February 2018-Present: Fellow of the American Academy of Neurology.
July 2003-Present: Fellow of Royal College of Paediatrics and Child Health, No: 17249, UK.
EDUCATION
(Awarded July 2007) MD THESIS “Therapeutic methods in Duchenne Muscular Dystrophy: short-term and long-term impact on the disease evolution and quality of life”, UNIVERSITY OF LONDON.
December 2000: Board certification in Paediatrics, University of Patras, Medical School, Greece.
July 1992: MBBS (Grade: very good), University of Patras, Medical School, Greece.
PROFESSIONAL ORGANISATIONS
May 2010-Present: MDU, membership No: 576497B.
September 2009-Present: BMA, membership No: 7768187.
February 1994-Present: UK General Medical Council, full membership No: 4077471.
2007-Present: British Paediatric Neurology Association, European Paediatric Neurology Society, American Academy of Neurology, World Muscle Society, Greek Paediatric Neurology Society and Hellenic Medical Society.
LEADERSHIP AND AWARDS
2014 and 2015: American Academy of Neurology (AAN) leadership programme for women (basic and advanced).
2017: Established leadership programme at CWHFT. Innovation award.
2016-2018: Clinical champion for Paediatrics for the PHG foundation and Medical Academy of Royal Colleges. Awarded via Professor Neena Modi, President of the RCPCH.
2016-2018: National clinical lead for rare diseases of the 100k genome project in the CWHFT; top recruiter in North West London of families with rare diseases.
GRANTS/FUNDING
ACADEMIC (1999-2010)
November 1999-November 2001: “Dubowitz Fellowship”, Dutch parents Project, The Netherlands.
April 2005-December 2008: Department of Health grant, Restoring Dystrophin Expression in Duchenne muscular dystrophy: Preclinical Optimisation and a Phase I/II Clinical Trial using a Morpholino Antisense Oligonucleotide, AVI 4658 -Grant awarded jointly to MDEX consortium, PI: Professor Francesco Muntoni funding for the duration of the project for Senior Clinical Fellowship at a Consultant Level.
2006-2009 institution reference: DMPED_P05241 Funder reference: LSHB-CT-2006-037479 Funder name: Commission of the European Communities Title: AMPLIFICATION OF HUMAN MYOGENIC STEM CELLS IN CLINICAL CONDITIONS (MYOAMP). Start date: 1 December 2006 End date: 30 November 2009 Description: CEC: AMPLIFICATION OF HUMAN MYOGENIC STEM CELLS IN CLINICAL CONDITIONS (MYOAMP). Funder type: EU COMMISSION.
2007-2008: co-applicant to MDC: A pilot study of Losartan in Duchenne Muscular Dystrophy
2007-2010: Association Française contre les Myopathies (AFM) and continues to be funded (initial year Euro 31,000 and similar funds annually): Targeted systemic gene therapy for Duchenne muscular Dystrophy.
NHS (2009-20018)
Neurophysiology department: funding for equipment (Ladies of parliament) £42,000 to set up an EEG telemetry service. Video EEG telemetry weekly revenue of over ¬£2,200 per patient per day admission.
Successful business case ongoing 2009: 2PA Consultant Paediatric Neuroradiology support.
Successful business case: for ANP in Epilepsy band 8, initial 2 years (Roald Dahl foundation) and ensuing from CWHFT, ongoing.
Successful business case: Additional FT 10 PA Consultant Paediatric neurology.
Successful business case: 2PA PT Consultant Paediatric Neurology via the RBH.
100 K project: over 200 exome patient samples (+additional parental exomes).
NHS PORTFOLIO STUDIES/ ACADEMIC COLLABORATIONS:
2009-2018
The Genetics of Human Epilepsy, portfolio number 8858 The CI is Prof Deb Pal.
Brain Function in Rolandic Epilepsy, portfolio number 12858 The CI is Prof Deb Pal.
Epilepsy in Infancy: relating genotype to phenotype, portfolio number CSP 127927/UKCRN 17483 The CI is Prof Helen Cross.
2018-Present
November 2020: Grant award co-recipient for £94,514 to support University College London efforts in developing a new ataxia service to support the 500 children with ataxia in the UK
Impact of CDD mutation on clinical phenotype: Professor Nicoletta Landsberger, Laboratorio di Biologia Molecolare e Cellulare applicate alle patologie del neurosviluppo, Universita’ degli Studi di Milano
Impact of CollVI mutations on immune dysregulation: Professor Kim Midwood, Professor of Matrix Biology, Kennedy Institute of Rheumatology, University of Oxford
British Paediatric Surveillance Unit: The impact of COVID-19 in children.
ENABLING ACTIVITIES
Reviewer: Neuromuscular disorders; European Journal of Paediatric Neurology; MRC grants; Paediatric Research Course lead for national meetings: Genomics in Clinical Practice meeting, Charing Cross Hospital, London, March 2017; Genetics for the clinician- Basics to brilliance, Royal Society of Medicine, London, January 2018
Scientific Advisory Board member: Amplexa genetics
PANDAS/PANS scientific consortium USA and UK (2019-Present).
PUBLICATIONS AND SCIENTIFIC PRESENTATIONS 84 peer-reviewed publications (h-index: 39, citations 5530, i10-index: 60, google scholar; scopus, h-index:36>100 scientific oral presentations, keynote presentations, and invited lectures, 2 book chapters.